Improved Quality of Life After 1 Year With an Invasive Versus a Noninvasive Treatment Strategy in Claudicants: One-Year Results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial
The evidence for revascularization in intermittent claudication (IC) is still of low quality, and the patient benefits with revascularization that are actually achieved remain unsettled. However, despite uncertain merits and risks for procedure-related complications, revascularization procedures are increasingly applied on IC patients. Most previous studies investigating the effects of revascularization in IC are hampered by selective inclusion criteria (ie, including only subgroups of patients with vascular lesions of a certain severity and length, located in specific vascular regions, and with suitability for endovascular procedures). Hence, there is currently a weak rationale for a generalization of existing evidence to the majority of IC patients. In this context, we performed a pragmatic real-world study, in which relatively unselected IC patients were randomly assigned to a primary invasive or a primary noninvasive treatment strategy and were followed for 1 year. The results in terms of health-related quality of life were assessed (primary end point) at 1 year, and secondary end points included treadmill walking capacity. We found that a primary invasive treatment strategy improved both health-related quality of life and claudication distance compared with a noninvasive strategy. The status with regard to health-related quality of life for the patients allocated to invasive treatment was comparable with that of an age-and sex-matched sample from the general population. Thus, a primary revascularization strategy improved health-related quality of life after 1 year substantially more than a noninvasive strategy in patients with IC, indicating that revascularization may be a valid treatment option for a larger group of IC patients. See p 939.
Troponin T and B-Type Natriuretic Peptide After OnPump Cardiac Surgery: Prognostic Impact on 12-Month Mortality and Major Cardiac Events After Adjustment for Postoperative Complications
Surgical risk stratification models focus on preoperative and intraoperative risk factors. This view may prove fragmentary postoperatively, because it disregards perioperative and early postoperative complications. Therefore, there is a need for tools that allow for early postoperative risk reassessment to guide management decisions. This prospective cohort study in 1559 patients undergoing on-pump cardiac surgery showed the independent association between troponin T ≥0.8 μg/L and B-type natriuretic peptides ≥790 ng/L within the first 2 postoperative days and 1-year all-cause mortality and major adverse cardiac events. This association persisted after adjustment considering preoperative and postoperative confounders. Extending the European System for Cardiac Operative Risk Evaluation to include postoperative troponin T and B-type natriuretic peptide information allowed for improved risk stratification in every fourth patient. The time window of ≈1 month between elevated biomarkers and events suggests that measurement of cardiac biomarkers flags high-risk patients early, that is, at a time point when management optimization holds promise for outcome improvement. See p 948.
Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure: Results From the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF)
Nesiritide is recombinant B-type natriuretic peptide approved for use in patients with acute heart failure, because of its ability to reduce pulmonary-capillary wedge pressure and improve dyspnea. Yet after its approval, it was suggested that nesiritide might cause renal toxicity and increase mortality. These concerns led to a marked decrease in the use of nesiritide. The Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) was conducted to re-evaluate the efficacy and safety of nesiritide, compared with placebo, added to standard of care in 7141 acute decompensated heart failure (ADHF) patients. Overall, compared with placebo, nesiritide did not worsen clinical outcomes. In the present renal retrospective analysis of the ASCEND-HF trial, we found that nesiritide did not have any effect on changes in creatinine during hospitalization in patients with ADHF. Furthermore, we examined the clinical predictors of changes in creatinine, and the relationship between changes in renal function and outcomes. At any time point during hospitalization, renal function as measured by creatinine was associated with 30-day death and 30-day death or rehospitalization including baseline, discharge, peak, change, or the most recent measure. We suggest measuring creatinine values more than once during hospitalization, for it is important to understand that the time of creatinine value ascertainment can yield differences in the association with outcomes. See p 958.
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999-2011
During the past decade, efforts focused intensely on improving the quality of care for people with, or at risk for, cardiovascular disease and stroke. This study sought to quantify the changes in hospitalization rates and outcomes for myocardial infarction, unstable angina, heart failure, and ischemic stroke from 1999 through 2011. The observed rates of hospitalization declined significantly for all targeted conditions across all age and sex-race groups. The adjusted 30-day and 1-year mortality rates also declined. This study reveals an era in the history of cardiovascular disease that was characterized by improvements in the rates of hospitalization and outcomes of 4 major cardiovascular conditions, with particular gains for myocardial infarction and unstable angina. See p 966.
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